
NYSE:UNH
This summary was created by AI, based on 32 opinions in the last 12 months.
UnitedHealth Group Inc (UNH) has seen mixed reviews from experts, with opinions fluctuating based on recent performance and external regulatory pressures. Some analysts express cautious optimism, noting that the company's fundamentals are improving and that it has potential for growth amid a challenging healthcare landscape. The return of the former CEO has sparked hope for effective cost management and operational improvements, potentially aiding in regaining investor confidence. However, there are concerns over high medical costs, regulatory scrutiny, and a turbulent political environment that could affect profitability. While some see opportunities for recovery and price appreciation, others highlight the risks associated with its reliance on Medicare funding and regulatory changes.
Allan Tong’s Discover Picks UNH it trades at 28.1x PE, which is slightly higher than its peers's average of 26.5x. Return on assets is higher, though, at 7.43% vs. 6.47% as is ROE at 21.88% vs. 18.86%. UNH stock's 1.36% may seem small, but it is in line with its peers and safe at a 34% payout ratio. The street loves this name at 14 buys and two holds, but sees only 7.5% upside from here. This isn't a trade a stock, but a long-term hold that you build on dips over time. It's enjoyed a 35% move in the past 12 months and has sharply climbed since Feb. 15. It's time for this to take a breather, which is the investor's cue to enter with a stock buying opportunity. Read Buying the Dip – A Stock Buying Opportunity for our full analysis.
This stock should skate through a change in administration or even another Trump term. Americans are quite happy with private healthcare solutions. 180M Americans have some sort of private health. 75% are happy with this so it would probably not be disrupted in a large way. He prefers Anthem but there is no problem with UNH.